We see the potential for a production vehicle with tremendous flexibility, which is a real alternative to Chinese hamster ovaries, the current industry standard. We have set ourselves a target of 25% of all new proteins and monoclonal antibodies. For anything in development and reaching the market between 2015 and 2020, we want 25% of the production platform to be PER.C6.

Leendert Staal